Kupiec-Weglinski J W, Tilney N L, Stunkel K G, Grutzmann R, van der Meide P H, Di Stefano R, Diamantstein T
Surgical Research Laboratory, Harvard Medical School, Boston, MA 02115.
Transplantation. 1989 Jan;47(1):11-6. doi: 10.1097/00007890-198901000-00004.
A panel of five mouse mAbs recognizing 4 distinct epitopes (R1-4) of the rat 55kD IL-2R molecule were tested for their influence on acute rejection (8 days) of (LEWxBN)F1 cardiac allografts in LEW hosts. IL-2R1 targeted therapy with ART-18 (IgG1, inhibits IL-2-dependent responses) prolonged graft survival to ca.21 days. IL-2R2 is recognized by ART-65 and ART-75, mAbs that do not inhibit T cell growth. Treatment with ART-65 (IgG1) but not ART-75 (IgG2a) abrogated acute rejection (ca. 16 days and 9 days, respectively). ART-35, an anti-IL-2R3 mAb (IgG1, does not inhibit T cell function) extended graft survival marginally to ca. 12 days. Finally, therapy with OX-39, (anti-R4 IgG1 mAb, inhibits IL-2 binding, but not IL-2-driven growth) was completely ineffectual. Simultaneous targeting of two IL-2R epitopes increased the therapeutic index synergistically (ART-18 [R1] + ART-65 [R2]--60% permanent graft acceptance), additively (ART-75 [R1] + ART-35 [R3]--graft survival ca. 18 days), or did not improve further graft survival at all (ART-18 [R1] + OX-39 [R4]--graft survival ca. 18 days). Thus, the cellular targeting patterns and isotype of mAbs are crucial: (1) targeting at functionally distinct epitopes controls rejection most effectively; (2) IgG1 and IgG2b mAbs are more influential in vivo than IgG2a, data supported by the studies employing the family of ART-18 isotype switch variants. Treatment with anti-IL-2R mAb did not depress Ts activity as tested both in vitro and in vivo. Sparing of putative Ts by mAb is also shown by thymectomy of graft recipients before or during ART-18 therapy, which shortened graft survival to 13-15 days; thymectomy after ART-18 therapy did not influence graft survival. However, infusion of IFN-gamma recreated classic acute rejection within 10 days in otherwise longstanding cardiac allografts in ART-18 treated hosts. Upregulation of MHC class II antigen and IL-2R expression seems to be primarily responsible for this striking biological effect of IFN-gamma in vivo.(ABSTRACT TRUNCATED AT 400 WORDS)
检测了一组可识别大鼠55kD白细胞介素-2受体(IL-2R)分子4个不同表位(R1 - 4)的五只小鼠单克隆抗体(mAb),以研究它们对LEW宿主中(LEWxBN)F1心脏异体移植急性排斥反应(8天)的影响。用ART-18(IgG1,抑制IL-2依赖性反应)进行IL-2R1靶向治疗可将移植物存活期延长至约21天。IL-2R2可被ART-65和ART-75识别,这两种mAb不抑制T细胞生长。用ART-65(IgG1)而非ART-75(IgG2a)治疗可消除急性排斥反应(分别约为16天和9天)。ART-35是一种抗IL-2R3 mAb(IgG1,不抑制T细胞功能),可使移植物存活期略微延长至约12天。最后,用OX-39(抗R4 IgG1 mAb,抑制IL-2结合,但不抑制IL-2驱动的生长)治疗则完全无效。同时靶向两个IL-2R表位可协同增加治疗指数(ART-18 [R1] + ART-65 [R2] - - 60%永久移植物接受)、相加增加(ART-75 [R1] + ART-35 [R3] - - 移植物存活约18天),或者根本不会进一步提高移植物存活期(ART-18 [R1] + OX-39 [R4] - - 移植物存活约18天)。因此,mAb的细胞靶向模式和同种型至关重要:(1)靶向功能不同的表位能最有效地控制排斥反应;(2)IgG1和IgG2b mAb在体内比IgG2a更具影响力,这一数据得到了使用ART-18同种型转换变体家族的研究所支持。如在体外和体内测试所示,用抗IL-2R mAb治疗不会降低Ts活性。在ART-18治疗前或治疗期间对移植物受体进行胸腺切除也表明mAb对假定的Ts有保留作用,这会将移植物存活期缩短至13 - 15天;ART-18治疗后进行胸腺切除则不影响移植物存活期。然而,在接受ART-18治疗的宿主中,向长期存活的心脏异体移植物中注入干扰素-γ可在10天内再次引发典型的急性排斥反应。MHC II类抗原和IL-2R表达的上调似乎是干扰素-γ在体内这种显著生物学效应的主要原因。(摘要截断于400字)